About Harmony Biosciences Holdings, Inc.
https://www.harmonybiosciences.comHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
CEO
Jeffrey M. Dayno
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 214
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:6.93M
Value:$249.61M
BLACKROCK INC.
Shares:5.84M
Value:$210.3M
VANGUARD GROUP INC
Shares:5.1M
Value:$183.7M
Summary
Showing Top 3 of 317
About Harmony Biosciences Holdings, Inc.
https://www.harmonybiosciences.comHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $239.46M ▲ | $114.32M ▲ | $50.87M ▲ | 21.24% ▲ | $0.88 ▲ | $73.46M ▲ |
| Q2-2025 | $200.49M ▲ | $114.16M ▲ | $39.78M ▼ | 19.84% ▼ | $0.69 ▼ | $59.25M ▼ |
| Q1-2025 | $184.73M ▼ | $96.49M ▲ | $45.56M ▼ | 24.66% ▲ | $0.8 ▼ | $66.98M ▲ |
| Q4-2024 | $201.27M ▲ | $91.13M ▲ | $49.48M ▲ | 24.58% ▼ | $0.87 ▲ | $66.33M ▼ |
| Q3-2024 | $186.04M | $81.55M | $46.09M | 24.78% | $0.81 | $72.49M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $672.58M ▲ | $1.21B ▲ | $373.1M ▲ | $835.12M ▲ |
| Q2-2025 | $565.27M ▲ | $1.11B ▲ | $334.93M ▼ | $773.08M ▲ |
| Q1-2025 | $506.95M ▲ | $1.06B ▲ | $335.01M ▼ | $720.52M ▲ |
| Q4-2024 | $467.19M ▲ | $999.2M ▲ | $340.05M ▲ | $659.15M ▲ |
| Q3-2024 | $410.48M | $928.13M | $331.33M | $596.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $50.87M ▲ | $108.73M ▲ | $-4.79M ▲ | $-3M ▼ | $100.95M ▲ | $108.66M ▲ |
| Q2-2025 | $39.78M ▼ | $79.33M ▲ | $-19.59M ▼ | $-2.69M ▼ | $57.05M ▲ | $79.32M ▲ |
| Q1-2025 | $45.56M ▼ | $33.99M ▼ | $2.36M ▲ | $-352K ▲ | $36M ▼ | $33.86M ▼ |
| Q4-2024 | $49.48M ▲ | $75.56M ▲ | $-7.19M ▼ | $-2.74M ▼ | $65.63M ▼ | $75.05M ▲ |
| Q3-2024 | $46.09M | $70.5M | $745K | $-1.18M | $70.07M | $70.5M |
Revenue by Geography
| Region | Q2-2023 | Q4-2023 | Q3-2023 | Q1-2023 |
|---|---|---|---|---|
 UNITED STATES | $500.00M ▲ | $0 ▼ | $500.00M ▲ | $500.00M ▲ |
CEO
Jeffrey M. Dayno
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 214
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:6.93M
Value:$249.61M
BLACKROCK INC.
Shares:5.84M
Value:$210.3M
VANGUARD GROUP INC
Shares:5.1M
Value:$183.7M
Summary
Showing Top 3 of 317